Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations

• Main Authors: Melinda J. Gooderham (Author), Marjolein de Bruin-Weller (Author), Stephan Weidinger (Author), Michael J. Cork (Author), Lawrence F. Eichenfield (Author), Eric L. Simpson (Author), Athanasios Tsianakas (Author), Urs Kerkmann (Author), Claire Feeney (Author), William Romero (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Abrocitinib, an oral, once-daily, Janus kinase (JAK) 1-selective inhibitor, is approved for the treatment of adults and adolescents with moderate-to-severe atopic dermatitis (AD). Abrocitinib has shown rapid and sustained efficacy in phase 3 trials and a consistent, manageable safety profil...